Douglass Winthrop Advisors LLC Boosts Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Douglass Winthrop Advisors LLC increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 7.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 471,533 shares of the medical research company’s stock after purchasing an additional 33,455 shares during the quarter. IQVIA accounts for 1.8% of Douglass Winthrop Advisors LLC’s portfolio, making the stock its 24th largest position. Douglass Winthrop Advisors LLC’s holdings in IQVIA were worth $92,661,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in IQV. Synergy Asset Management LLC purchased a new position in IQVIA in the 4th quarter valued at about $33,000. Avior Wealth Management LLC lifted its stake in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares in the last quarter. Meeder Asset Management Inc. boosted its holdings in IQVIA by 353.7% in the third quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 191 shares during the last quarter. Versant Capital Management Inc increased its holdings in IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after purchasing an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in shares of IQVIA in the 4th quarter valued at approximately $60,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 1.5 %

IQVIA stock opened at $184.13 on Friday. The firm has a 50-day moving average price of $195.30 and a two-hundred day moving average price of $209.18. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $256.29. The firm has a market capitalization of $32.46 billion, a price-to-earnings ratio of 24.55, a PEG ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on IQV shares. Morgan Stanley lifted their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Stephens assumed coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price for the company. Truist Financial reaffirmed a “buy” rating and set a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. JPMorgan Chase & Co. lowered their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Finally, StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.